We are live on ! Find out more
ANIP icon

ANI Pharmaceuticals
ANIP

175 hedge funds and large institutions have $386M invested in ANI Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 50 increasing their positions, 55 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 15

7% more funds holding

Funds holding: 163 → 175 (+12)

0.62% more ownership

Funds ownership: 56.22% → 56.85% (+0.62%)

9% less repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 55

9% less capital invested

Capital invested by funds: $422M → $386M (-$36.3M)

28% less call options, than puts

Call options by funds: $8.14M | Put options by funds: $11.4M

Holders
175
Holders Change
+12
Holders Change %
+7.36%
% of All Funds
4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
30
Increased
50
Reduced
55
Closed
15
Calls
$8.14M
Puts
$11.4M
Net Calls
-$3.23M
Net Calls Change
+$15.1M

Top Buyers

Rank Fund Capital Flow
1
LSV Asset Management
LSV Asset Management
Illinois
+$17.8M
2
Goldman Sachs
Goldman Sachs
New York
+$2.98M
3
Millennium Management
Millennium Management
New York
+$2.81M
4
AIA
Avalon Investment & Advisory
Texas
+$2.8M
5
BIM
Bogle Investment Management
Massachusetts
+$2.71M

Top Sellers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
-$15.8M
2
ICOM
Investment Counselors of Maryland
Maryland
-$3.96M
3
Bank of New York Mellon
Bank of New York Mellon
New York
-$3.94M
4
Renaissance Technologies
Renaissance Technologies
New York
-$3.66M
5
NC
Nexthera Capital
New York
-$2.7M

ANIP Hedge Fund Activity: Q1 2018 in Review

175 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q1 2018, worth a combined $386M — down 8.6% from $422M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new ANIP positions and 15 closed out — a net gain of 15 holders — while 50 added to existing stakes and 55 trimmed.

The largest buyer was LSV Asset Management, adding an estimated $17.8M. The largest seller was Invesco, cutting an estimated $15.8M.

  • 175 institutional investors held ANI Pharmaceuticals (ANIP) as of Q1 2018, up from 163 in Q4 2017.
  • Funds reported $386M of ANI Pharmaceuticals stock for Q1 2018, down 8.6% quarter-over-quarter.
  • 30 funds opened new ANI Pharmaceuticals positions in Q1 2018 and 15 closed out, a net change of +15 holders.
  • The largest ANI Pharmaceuticals buyer in Q1 2018 was LSV Asset Management, an estimated $17.8M added.
  • The largest ANI Pharmaceuticals seller in Q1 2018 was Invesco, an estimated $15.8M sold.

Based on aggregated 13F filings for Q1 2018.